Litcius/Paper detail

Ultrasound-activated erythrocyte membrane-camouflaged Pt (II) layered double hydroxide enhances PD-1 inhibitor efficacy in triple-negative breast cancer through cGAS-STING pathway-mediated immunogenic cell death

Yanjie Wu, Zhiyu Zhao, Mengli Ma, Weijin Zhang, Wei Liu, Xiaochen Liang, Ting Zhao, Yi Luo, Yunjie Wang, Mengqi Li, Tingting Li, Cong Liu, Xian Luo, Shengyu Wang, Wanyun Li, Wei‐Cai Zeng, Hong Wang, Wengang Li, Ting Wu, Zhihai Ke, Fanghong Luo

2024Theranostics22 citationsDOIOpen Access PDF

Abstract

The integration of RmPLH with PD-1 inhibitors substantially amplifies ICD, fostering robust antigen-specific T cell immunity and offering a promising therapeutic strategy for TNBC. This study represents a pioneering application of Pt (II)-based LDH nanocages in oncology, laying a foundation for future innovations in tumor immunotherapy.

Topics & Concepts

Triple-negative breast cancerStingCancer researchChemistryProgrammed cell deathMedicineBreast cancerCancerPharmacologyCell biologyApoptosisInternal medicineBiologyBiochemistryEngineeringAerospace engineeringNanoplatforms for cancer theranosticsPeptidase Inhibition and AnalysisGa2O3 and related materials
Ultrasound-activated erythrocyte membrane-camouflaged Pt (II) layered double hydroxide enhances PD-1 inhibitor efficacy in triple-negative breast cancer through cGAS-STING pathway-mediated immunogenic cell death | Litcius